Jade Biosciences, Inc. JBIO
14.42
(0.31)
(2.10%)
as of 25 Sep
- Market cap
- $936.8M
- P/E
- 0.0×
Follow JBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(60.21%) | (70.09%) | (55.09%) | (39.27%) | |
| (53.32%) | (47.39%) | (51.56%) | (36.19%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(43.65%) | (30.12%) | (34.53%) | (28.64%) | |
Free Cash Flow per Share |
(1.95) | (3.03) | (1.73) | (2.02) | |
Free Cash Flow |
(77.14) | (94.95) | (100.01) | (123.51) | |
Capital Expenditures |
(0.29) | (0.26) | — | — | |
| Other line items | |||||
Cash ROIC |
(20.32%) | (14.16%) | (16.46%) | (13.71%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.98 | 0.95 | 0.98 | 0.98 | |
Depreciation/Fixed assets |
(13.32) | (5.76) | (7.91) | (11.08) | |
Capex/Depreciation |
0.12 | 0.27 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.94) | (3.02) | (1.73) | (2.02) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates